Without J&J, Capricor Plans To Advance Progenitor Cell Therapy In DMD
Executive Summary
California biotech says it will move forward with knowledge and expertise gained through the failed partnership. Capricor hopes to re-partner CAP-1002 for cardiovascular indications, while continuing the candidate’s DMD development itself.